The role of tumor-derived exosomes in tumor immune escape: A concise review

Nhat Chau Truong¹², Thao Nhi Huynh²³, Khuong Duy Pham²³, Phuc Van Pham¹²³⁴⁺©

ABSTRACT

Exosomes are small vesicles secreted by viable cells into the microenvironment. These vesicles bring various compositions, including lipids, RNAs and proteins, which carry information from producer cells to target cells. Cancer cells also produce exosomes, termed as tumor-derived exosomes (TDEs), which play important roles in immune modulation, angiogenesis and metastasis of tumors. This review summarizes the roles of TDEs in tumor immune escape mechanisms. TDEs affect all kinds of tumor-associated immune cells, including natural killer (NK) cells, dendritic cells (DCs), T and B lymphocytes, and myeloid-derived suppressor cells (MDSCs). Generally, TDEs suppress the immune system to promote tumor immune escape, thereby significantly contributing to tumorigenesis and metastasis.

Key words: Cancer, Exosomes, Tumor immune escape

INTRODUCTION

The environment surrounding cancer cells, i.e. the local cellular environment in which tumors exist, is termed the tumor microenvironment (TME). The TME plays an important role in protecting tumors from the immune system¹, as well as other pro-tumorigenic roles. The TME is surrounded by blood vessels, myofibroblasts, immune cells (such as monocytes, macrophages, T lymphocytes, B lymphocytes, and natural killer (NK) cells), as well as non-cellular compositions (such as the extracellular matrix (ECM), signaling factors, and cytokines)². Recently, in the TME, another non-cellular composition was discovered which has important roles in tumorigenesis and metastasis; this component was extracellular vesicles (EVs). The EVs in the TME is derived from several types of cells, including cancer cells and normal cells. There have been at least 3 types of EVs discovered in the TME: exosomes (derived from both cancerous and normal cells), microvesicles (derived from both cancerous and normal cells), and oncosomes (derived from cancerous cells) (Figure 1). To distinguish the exosomes from normal cells, exosomes secreted by the cells inside a tumor are termed tumor-derived exosomes (TDEs).

TDEs are involved in both development and metastasis of cancer via angiogenesis and immunosuppressive factors (which are carried within the vesicles)³. TDEs play a vital role of communication between cancer cells and the host environment in cancer metastasis¹. Cancer cells also produce their own exosomes, term as cancer cell-derived exosomes (CDEs). In this concise review, we will just focus on the role of TDEs in tumor immune escape.

TUMOR-DERIVED EXOSOMES (TDES)

Exosomes are small membrane vesicles, ranging in size from 30–150 nm, and with a density of 1.10–1.14 g/ml. They are known to have a critical role in cell–cell communication. Due to the small dimensions, exosomes are visualized by electron microscopy²–⁶. In nature, exosomes were originally intraluminal vesicles released from late endosome multivesicular bodies (MVBs) after fusing with the plasma membrane⁴. Exosomes can be secreted by many cell types, including immune cells and cancer cells². The exosome structure consists of an outer lipid bilayer membrane, which encapsulates contents such as proteins, lipids, DNAs (e.g. mtDNA, ssDNA, and dsDNA), RNAs (e.g. lncRNAs, miRNAs, and mRNA), among other components. Exosomes exert their functions after delivery to or interaction with recipient cells²,¹.

The boundaries between markers and packaged components within an exosome are rather ambiguous. In essence, the TDEs may contain all the constituent components of the tumor, including those from the TME. Some typical proteins found on the surface of TDEs are tetraspanins, endosomal sorting complexes required for transport (ESCRT), membrane transport and fusion proteins, adhesive proteins, heat shock...
Figure 1: Tumor environment with various kinds of cells and their extracellular vesicles. Almost cells in this environment produce and secrete exosomes and microvesicles into the extracellular fluid. Some cancer cells produce oncosomes to contribute to this environment.

proteins, enzymes, receptor proteins, MHC I/II, integrins, PD-L1, EGFR, and TRAIL. On the contrary, in non-metastatic cells, the predominant proteins found are cell adhesion-related proteins. Alix and TSG101 are molecular markers specific for exosomes that are related to multivesicular body (MVB) formation. Tetraspanins, flotillin-1, integrins, and MHC I/II represent several membrane proteins, while Hsp70, TSG101, and Alix are cytosolic proteins. Other proteins, as well as mRNA, miRNA, non-coding RNA, and DNAs, are found in exosomes, depending on the specific origin of those exosomes.

The encapsulation of biological molecules into the exosome involves the action of ESCRTs. These molecules are also involved in the secretion of exosomes outside the cell. TDEs often contain tumor-specific antigens expressed in the parental tumor cells; some examples are melan-A, Silv, carcinoembryonic antigen (CEA), and mesothelin. These antigens are presumably transferred to dendritic cells (DCs) and can induce CD8+ T cell-dependent antitumor effects in both mice and humans. The transfer of contents in exosomes is specific to ligands or signals on the recipient cells and exosomes.

Besides facilitating effects which promote tumor progression and invasion, there are factors within TMEs which can inhibit antitumor immunity by promoting immunosuppression. The TME of TDEs are different
from other local cellular environments in that the vasculature is poorly organized, creating a hypoxic environment which significantly hinders the transfer of many types of molecules. In inflammation and cancer, there are common molecules and signaling pathways, such as nuclear factor kappa B (NFκB), signal transducer and activator of transcription 3 (STAT3), interleukin (IL)-1β, IL-6, and tumor necrosis factor alpha (TNF-α). NFκB has been demonstrated to be related to the antitumor and pro-tumor properties of macrophages.

**IMMUNE-REGULATORY ACTIVITIES OF TUMOR-DERIVED EXOSOMES ON IMMUNE CELLS**

**Natural Killer (NK) Cells**

NK cell-derived exosomes contain cellular perforin and granzyme B. TDEs were compared to NK cell-derived exosomes for their ability to neutralize these substances. Reduced expression of MHC I is one of the mechanisms by which cancer cells used to escape from T-cell recognition. However, this is not a barrier for NK cells since they possess a large number of target recognition receptors and do not require the need for T cell receptors (TCRs/CD3). Fas ligand (FasL) found in the structural components of exosomes derived from cancer cells can be cytotoxic to NK cells. The expression of PD-L1 mRNA in exosomes may outweigh the effects of anti-PD1 antibody treatment as another way for the cancer to escape immunotherapy. The ligand of NKG2D is an induced self-protein which is rarely manifested in normal cells, but is over-expressed in cells that are transformed, infected, stressed, or aging. It was shown that TDEs express ligands for NKG2D and down-regulate these receptors on NK cells. Liu et al. (2006) showed that TDEs blocked IL-2-mediated perforin production of NK cells, and blocked expression of JAK3; cyclin D3 then prevented NK cells from entering the cell cycle. TDEs carry a complex of MIC ligand A and B that bind to NK, impairing the ability of these cells to recognize tumor cells while reducing the expression of NKG2D receptors on the surface of NK cells.

**CD8⁺ T-cells**

According to Maybrick et al. (2017), induction of purified CD3⁺CD8⁺ T cells by exosomes derived from head and neck squamous cell carcinoma (HNSCC) elicited the suppressor phenotype (SP), causing the loss of CD27/CD28 expression and attenuation of interferon gamma (IFN-γ) production. SP CD3⁺CD8⁺ T cells are also capable of inhibiting CD3⁺CD8⁺ T cells outside the tumor. This inhibitory phenotype is driven not only by the protein content but also by the mRNA content of the exosomes. Liu et al. (2020) demonstrated that exosomes isolated from gastric cancer cell lines created an immunosuppressive TME in vivo by increasing numbers of effector memory CD4⁺ T cells and myeloid-derived suppressor cells (MDSCs), decreasing CD8⁺ T cell function (e.g. apoptosis) and NK frequency/function, and promoting gastric cancer lung metastasis. Simultaneously, gastric cancer cell lines also increased their secretion of IL-2, IL-6, IL-10, and IFN-γ; among them, IL-10 levels increased the greatest (up to 12-19-fold). The IL-10 increase was accompanied by expression of immune suppressive genes, such as FOXP3, in TDEs (from the tumor derived CD8⁺ T cells). Exosomal FasL and TNF-related apoptosis-inducing ligand (TRAIL)-bound in TDEs can also induce apoptosis of activated CD8⁺ T cells. The TME has an important role in the polarization of CD8⁺ T lymphocyte sub-population. The majority of APCs in TME and tertiary lymphoids are dysfunctional and produce altered cytokine profiles and co-stimulatory molecules, which greatly influence the lineage commitment of CD8⁺ T cells. The engagement between MHC I (of TDEs) and CD8 receptor (of T cells) leads to apoptosis of T cells via the activation of the Fas/FasL signaling pathway.

**CD4⁺ T-cells**

Exosomes derived from gastric cancer showed a decreased frequency of naïve T cells but increased frequency of effective memory T cells (CD62⁺CD44hi). Studies have shown that TDEs promote Treg and MDSC expansion, TDEs can indirectly activate CD4⁺ T cells and inhibit the activity of CD8⁺ T cells through cancer-associated fibroblasts (CAFs). Exosomes derived from nasopharyngeal carcinoma inhibit Th1 and Th17 differentiation and induce Treg differentiation in vitro. According to Laurent et al. (2016), TDEs decreased the expression of CD69 on the surface of activated CD4⁺ T cells, and increased adenosine production of Tregs in a ligand-receptor, but not internalized pattern. For CAR T cell-based therapy in the treatment of neuroblastoma, TDEs counteracted the effects of CD4⁺ T cells, but not CD8⁺ T cells.

**Dendritic cells (DCs)**

DCs are the most professional antigen-presenting cells (APCs) of the immune system. Exosomes from gastric cancer cell lines were taken up by NKs...
As exosomes are able to target cancers, they hold promise for the treatment of various types of cancers. In many cases, exosomes may be a better target than the cancer itself, as they can be used to deliver cancer drugs because of their ability to home back to their origin. The raw materials for production of such vaccines can be obtained from a variety of biological fluids and do not deteriorate when stored for long periods of time. Furthermore, the development of drugs targeting the galectin-1 constituents of exosomes holds promise in the treatment of many types of cancer. Elimination of exosomal PD-L1 inhibited tumor proliferation, even in an anti-PD-L1 antibody mouse model. The application of TDEs, in general, and CDEs, in particular, is very promising. However, more research is needed to apply advanced technologies based on exosomes for cancer diagnosis, prognosis, treatment and control.

**ABBREVIATIONS**

APCs: antigen-presenting cells  
CAFcs: cancer-associated fibroblasts  
CDEs: cancer cell-derived exosomes  
CEA: carcinoembryonic antigen  
DCs: dendritic cells  
ECM: extracellular matrix  
EGFR: epidermal growth factor receptor  
ESCRT: endosomal sorting complexes required for transport  
EVs: extracellular vesicles  
FasL: Fas ligand  
HNSCC: head and neck squamous cell carcinoma  
IFN-g: interferon gamma  
MDSCs: myeloid-derived suppressor cells  
MVBs: multivesicular bodies  
NFkB: nuclear factor kappa B  
PGE2: prostaglandin E2  
ROS: reactive oxygen species  
SP: suppressor phenotype  
STAT3: signal transducer and activator of transcription  
TCRs: T cell receptors  
TDEs: tumor-derived exosomes  
TME: tumor microenvironment  
TRAIL: TNF-related apoptosis-inducing ligand
ACKNOWLEDGMENTS

None.

AUTHOR’S CONTRIBUTIONS

All authors equally contributed in this work. All authors read and approved the final manuscript.

FUNDING

None.

AVAILABILITY OF DATA AND MATERIALS

Not applicable.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Not applicable.

CONSENT FOR PUBLICATION

Not applicable.

COMPETING INTERESTS

The authors declare that they have no competing interests.

REFERENCES


